Literature DB >> 23097443

Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor.

Chee Wah Tan1, Chit Laa Poh, I-Ching Sam, Yoke Fun Chan.   

Abstract

Enterovirus 71 (EV-71) infections are usually associated with mild hand, foot, and mouth disease in young children but have been reported to cause severe neurological complications with high mortality rates. To date, four EV-71 receptors have been identified, but inhibition of these receptors by antagonists did not completely abolish EV-71 infection, implying that there is an as yet undiscovered receptor(s). Since EV-71 has a wide range of tissue tropisms, we hypothesize that EV-71 infections may be facilitated by using receptors that are widely expressed in all cell types, such as heparan sulfate. In this study, heparin, polysulfated dextran sulfate, and suramin were found to significantly prevent EV-71 infection. Heparin inhibited infection by all the EV-71 strains tested, including those with a single-passage history. Neutralization of the cell surface anionic charge by polycationic poly-d-lysine and blockage of heparan sulfate by an anti-heparan sulfate peptide also inhibited EV-71 infection. Interference with heparan sulfate biosynthesis either by sodium chlorate treatment or through transient knockdown of N-deacetylase/N-sulfotransferase-1 and exostosin-1 expression reduced EV-71 infection in RD cells. Enzymatic removal of cell surface heparan sulfate by heparinase I/II/III inhibited EV-71 infection. Furthermore, the level of EV-71 attachment to CHO cell lines that are variably deficient in cell surface glycosaminoglycans was significantly lower than that to wild-type CHO cells. Direct binding of EV-71 particles to heparin-Sepharose columns under physiological salt conditions was demonstrated. We conclude that EV-71 infection requires initial binding to heparan sulfate as an attachment receptor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23097443      PMCID: PMC3536405          DOI: 10.1128/JVI.02226-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Crystal structure of human enterovirus 71.

Authors:  Pavel Plevka; Rushika Perera; Jane Cardosa; Richard J Kuhn; Michael G Rossmann
Journal:  Science       Date:  2012-03-01       Impact factor: 47.728

2.  Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2.

Authors:  Pan Chen; Zilin Song; Yonghe Qi; Xiaofeng Feng; Naiqing Xu; Yinyan Sun; Xing Wu; Xin Yao; Qunyin Mao; Xiuling Li; Wenjuan Dong; Xiaobo Wan; Niu Huang; Xinliang Shen; Zhenglun Liang; Wenhui Li
Journal:  J Biol Chem       Date:  2012-01-04       Impact factor: 5.157

3.  Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71.

Authors:  Seiya Yamayoshi; Setsuko Iizuka; Teruo Yamashita; Hiroko Minagawa; Katsumi Mizuta; Michiko Okamoto; Hidekazu Nishimura; Kanako Sanjoh; Noriko Katsushima; Tsutomu Itagaki; Yukio Nagai; Ken Fujii; Satoshi Koike
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

Review 4.  Virology, epidemiology, pathogenesis, and control of enterovirus 71.

Authors:  Tom Solomon; Penny Lewthwaite; David Perera; Mary Jane Cardosa; Peter McMinn; Mong How Ooi
Journal:  Lancet Infect Dis       Date:  2010-10-18       Impact factor: 25.071

5.  Scavenger receptor B2 is a cellular receptor for enterovirus 71.

Authors:  Seiya Yamayoshi; Yasuko Yamashita; Jifen Li; Nobutaka Hanagata; Takashi Minowa; Taro Takemura; Satoshi Koike
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

6.  Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences.

Authors:  Yoke-Fun Chan; I-Ching Sam; Sazaly AbuBakar
Journal:  Infect Genet Evol       Date:  2009-05-22       Impact factor: 3.342

Review 7.  Clinical features, diagnosis, and management of enterovirus 71.

Authors:  Mong How Ooi; See Chang Wong; Penny Lewthwaite; Mary Jane Cardosa; Tom Solomon
Journal:  Lancet Neurol       Date:  2010-11       Impact factor: 44.182

8.  A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71.

Authors:  Xiangxi Wang; Wei Peng; Jingshan Ren; Zhongyu Hu; Jiwei Xu; Zhiyong Lou; Xumei Li; Weidong Yin; Xinliang Shen; Claudine Porta; Thomas S Walter; Gwyndaf Evans; Danny Axford; Robin Owen; David J Rowlands; Junzhi Wang; David I Stuart; Elizabeth E Fry; Zihe Rao
Journal:  Nat Struct Mol Biol       Date:  2012-03-04       Impact factor: 15.369

9.  Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells.

Authors:  Betsy Yang; Hau Chuang; Kuender D Yang
Journal:  Virol J       Date:  2009-09-15       Impact factor: 4.099

10.  Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1.

Authors:  Chee Wah Tan; Yoke Fun Chan; Kooi Mow Sim; Eng Lee Tan; Chit Laa Poh
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

View more
  95 in total

1.  Human astrocytic cells support persistent coxsackievirus B3 infection.

Authors:  Xiaowei Zhang; Zhenhua Zheng; Bo Shu; Xijuan Liu; Zhenfeng Zhang; Yan Liu; Bingke Bai; Qinxue Hu; Panyong Mao; Hanzhong Wang
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

2.  Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry.

Authors:  Zhiqiang Ku; Xiaohua Ye; Jinping Shi; Xiaoli Wang; Qingwei Liu; Zhong Huang
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

3.  Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.

Authors:  Chen Fan; Xiaohua Ye; Zhiqiang Ku; Liangliang Kong; Qingwei Liu; Cong Xu; Yao Cong; Zhong Huang
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 4.  Is a multivalent hand, foot, and mouth disease vaccine feasible?

Authors:  Michel Klein; Pele Chong
Journal:  Hum Vaccin Immunother       Date:  2015-05-26       Impact factor: 3.452

5.  Amino Acid Variation at VP1-145 of Enterovirus 71 Determines Attachment Receptor Usage and Neurovirulence in Human Scavenger Receptor B2 Transgenic Mice.

Authors:  Kyousuke Kobayashi; Yui Sudaka; Ayako Takashino; Ayumi Imura; Ken Fujii; Satoshi Koike
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

6.  VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection.

Authors:  Ken Fujii; Yui Sudaka; Ayako Takashino; Kyousuke Kobayashi; Chikako Kataoka; Tadaki Suzuki; Naoko Iwata-Yoshikawa; Osamu Kotani; Yasushi Ami; Hiroyuki Shimizu; Noriyo Nagata; Katsumi Mizuta; Yoko Matsuzaki; Satoshi Koike
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

7.  Identification of Positively Charged Residues in Enterovirus 71 Capsid Protein VP1 Essential for Production of Infectious Particles.

Authors:  Shilin Yuan; Guiming Li; Ying Wang; Qianqian Gao; Yizhuo Wang; Rui Cui; Ralf Altmeyer; Gang Zou
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

8.  Mutations in VP1 and 3A proteins improve binding and replication of rhinovirus C15 in HeLa-E8 cells.

Authors:  Yury A Bochkov; Kelly Watters; Sarmila Basnet; Shakher Sijapati; Marchel Hill; Ann C Palmenberg; James E Gern
Journal:  Virology       Date:  2016-10-13       Impact factor: 3.616

9.  Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.

Authors:  Xiaoli Wang; Zhiqiang Ku; Xiang Zhang; Xiaohua Ye; Jinhuan Chen; Qingwei Liu; Wei Zhang; Chao Zhang; Zhenglin Fu; Xia Jin; Yao Cong; Zhong Huang
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

10.  A Single Mutation in the VP1 of Enterovirus 71 Is Responsible for Increased Virulence and Neurotropism in Adult Interferon-Deficient Mice.

Authors:  Elizabeth A Caine; Louise H Moncla; Monica D Ronderos; Thomas C Friedrich; Jorge E Osorio
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.